Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
About Clearmind Medicine Inc. (CMND)
Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0) is a clinical-stage psychedelic pharmaceutical biotechnology company pioneering the development of novel psychedelic-derived therapeutics to address widespread and underserved health challenges. With a focus on non-hallucinogenic compounds, Clearmind aims to transform the treatment landscape for conditions such as alcohol use disorder (AUD), binge behavior, and other mental health disorders.
Innovative Therapeutic Solutions
The company’s flagship therapeutic, MEAI (5-methoxy-2-aminoindane), is a groundbreaking psychoactive molecule designed to regulate binge behaviors, including alcohol consumption, while providing a mild euphoric experience. MEAI-based treatments, such as CMND-100, are currently undergoing clinical trials to evaluate their safety, tolerability, and efficacy. Clearmind’s Phase I/IIa clinical trials, conducted in collaboration with leading institutions like Yale School of Medicine and Johns Hopkins University, underscore its commitment to rigorous scientific validation.
Expanding Intellectual Property Portfolio
Clearmind boasts an extensive and growing intellectual property (IP) portfolio, comprising 31 granted patents across 19 patent families, with protections secured in key jurisdictions such as the U.S., Europe, China, and India. This robust IP strategy covers innovative compounds, combination therapies, and delivery methods, ensuring the company’s competitive edge in the psychedelic pharmaceutical space. Recent patents include novel combinations of MEAI with N-Acylethanolamines and other compounds to enhance therapeutic efficacy and safety.
Collaborative Approach
Collaboration is central to Clearmind’s innovation strategy. The company partners with academic institutions like the Hebrew University of Jerusalem through Yissum Research Development Company and pharmaceutical firms such as SciSparc Ltd. These partnerships enable the development of next-generation psychedelic therapies targeting complex conditions like post-traumatic stress disorder (PTSD), opioid use disorder (OUD), and more.
Market Potential and Social Impact
Clearmind operates within the rapidly growing psychedelic therapeutics market, driven by increasing recognition of psychedelics’ potential in mental health treatment. The global market for AUD and PTSD treatments alone represents billions in unmet demand. Clearmind’s innovative solutions, such as its MEAI-based alcohol alternative developed in collaboration with Dr. Glitter Pty Ltd, aim to address these gaps by offering safer, non-addictive alternatives to traditional treatments.
Commitment to Safety and Accessibility
Clearmind’s therapeutic pipeline emphasizes safety and accessibility. By focusing on non-hallucinogenic psychedelic compounds, the company seeks to minimize risks while maximizing therapeutic benefits. This approach aligns with its mission to improve quality of life for patients worldwide, particularly those struggling with addiction and mental health disorders.
Future Outlook
As a pioneer in the psychedelic pharmaceutical industry, Clearmind Medicine Inc. is well-positioned to lead the next wave of innovation in mental health and addiction treatment. Its strategic focus on intellectual property, clinical validation, and collaborative partnerships underscores its potential to revolutionize the field and deliver transformative solutions to global healthcare challenges.
Clearmind Medicine (Nasdaq: CMND) has announced the publication of a patent by Mexico's National Patent Office (IMPI) for its combination therapy treatment. The patent covers an innovative treatment combining MEAI and N-Acylethanolamines, targeting various binge behaviors including alcohol, eating, tobacco, shopping, and sexual conduct.
The patent emerged from Clearmind's collaboration with SciSparc (Nasdaq: SPRC), focusing on developing treatments for central nervous system disorders. The partnership aims to research combination therapies that integrate psychedelic compounds with N-Acylethanolamines family, including Palmitoylethanolamide (PEA).
Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech company developing psychedelic-derived therapeutics, announced the successful approval of all matters presented at its January 6, 2025 shareholders meeting. Key approvals include:
- Setting the board of directors at five members
- Election of directors for the upcoming year
- Appointment of Brightman Almagor Zohar & Co. (Deloitte Global Network) as company auditor
- Establishment of an omnibus equity incentive plan
- Authorization for potential share consolidation up to 50:1 ratio at board's discretion
Clearmind Medicine (Nasdaq: CMND) announced the publication of a European patent application for its combination therapy using MEAI and N-Acylethanolamines. The therapy targets various binge behaviors, including alcohol, eating, tobacco, shopping, and sexual conduct.
The patent stems from Clearmind's collaboration with SciSparc (Nasdaq: SPRC), focusing on combining psychedelic compounds with N-Acylethanolamines family, including Palmitoylethanolamide (PEA). The company has filed 13 patents across multiple jurisdictions related to this collaboration, strengthening its intellectual property portfolio in psychedelic therapies for binge behavior treatment.
Clearmind Medicine (NASDAQ: CMND) has received patent approval from the Macau International Intellectual Property Office for its MEAI-based binge behavior regulator program. The patent covers primary amine aminoindan compounds, including but not to 5-methoxy-2-aminoindan (MEAI), for regulating binge behavior.
This addition to Clearmind's intellectual property portfolio brings their total to 31 granted patents across 18 patent families, with coverage in major jurisdictions including the US, Europe, China, India, Hong Kong, and Macau. The company focuses on developing non-hallucinogenic proprietary molecules for treating substance addictions related to alcohol and food.
Clearmind Medicine (NASDAQ: CMND) has signed a non-binding term sheet with Dr Glitter Pty to develop and commercialize a novel MEAI-based alcohol substitute using Dr Glitter's ActivCrystal™ technology. The collaboration aims to create a product that replicates alcohol's sensations without health risks or hangovers.
The ActivCrystal™ format consists of tasteless, odorless crystals made from natural ingredients that can be sprinkled on meals. Users will be able to adjust dosage individually by sprinkling the MEAI-based alternative into beverages or food. This partnership represents a strategic move in Clearmind's efforts to bring MEAI to global markets as a solution to combat alcohol misuse.
Clearmind Medicine (NASDAQ: CMND) has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial will be conducted at Yale School of Medicine's Department of Psychiatry under Dr. Anahita Bassir Nia's leadership. This FDA-regulated clinical program aims to evaluate the safety, tolerability, and efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD.
The development addresses a significant global health issue, as alcohol consumption causes 2.6 million deaths annually worldwide and represents 4.7% of global deaths. Current AUD treatments face challenges including high costs, low efficacy (less than 30%), and poor patient compliance due to side effects.
Clearmind Medicine (NASDAQ: CMND) has signed a non-binding term sheet with Dr. Glitter Pty to develop and commercialize a novel MEAI-based alcohol substitute using ActivCrystal™ technology. The collaboration aims to create a product that replicates alcohol's sensations without health risks or hangovers.
The ActivCrystal™ technology encapsulates active ingredients in tasteless, odorless crystals made from natural ingredients that can be sprinkled on meals. Upon finalizing a definitive agreement, the product will allow users to add MEAI-based crystals to their choice of beverage or food with adjustable dosage.
This partnership represents a strategic move in Clearmind's efforts to introduce MEAI to global markets as a solution to combat alcohol misuse.
Clearmind Medicine Inc. (Nasdaq: CMND) has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, a MEAI-based treatment for alcohol use disorder (AUD). This approval marks the second clinical site for the multinational, multi-center trial, which will assess the safety, tolerability, and pharmacokinetics of CMND-100.
The trial will take place at Johns Hopkins University, Yale School of Medicine, and IMCA Center in Israel. Clearmind has already secured FDA approval for its Investigational New Drug (IND) application in the U.S. and approval from the Israeli Ministry of Health.
The primary endpoint of the trial is to determine the tolerable dose and evaluate the safety, pharmacokinetics, and pharmacodynamics of CMND-100. This milestone brings Clearmind closer to offering a potential solution for AUD, which is a major global health issue and the most common substance use disorder among people aged 12 and older in the U.S.
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of an international patent application for a pioneering combination therapy of Ibogaine and N-Acylethanolamines. This innovative treatment, developed in collaboration with SciSparc (Nasdaq: SPRC), aims to enhance safety and efficacy in mental health and addiction care.
Ibogaine, derived from the Tabernanthe iboga shrub, has shown promise in treating various substance use disorders. The combination with N-Acylethanolamines, including Palmitoylethanolamide (PEA), is expected to further improve the therapy's effectiveness and safety profile. This development underscores Clearmind's commitment to leadership in the psychedelics space and its focus on providing safe solutions for unmet mental health needs.
Clearmind Medicine Inc. (Nasdaq: CMND) has filed an international patent application for innovative psychedelic compounds designed to treat post-traumatic stress disorder (PTSD) and other mental health conditions. This application is part of Clearmind's collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The compounds were invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel.
The global PTSD treatment market, valued at $16.8 billion in 2023, is projected to reach $27.37 billion by 2033. Current PTSD treatments offer efficacy, and FDA-approved drugs often come with side effects. Clearmind aims to develop effective and safe next-generation psychedelic compounds to significantly improve patients' quality of life.
FAQ
What is the current stock price of Clearmind Medici (CMND)?
What is the market cap of Clearmind Medici (CMND)?
What does Clearmind Medicine Inc. specialize in?
What is MEAI and how is it used?
What is Clearmind’s approach to intellectual property?
Who are Clearmind’s key collaborators?
What market needs does Clearmind address?
How does Clearmind ensure safety in its treatments?
What is Clearmind’s alcohol alternative product?
What differentiates Clearmind from competitors?
